Population pharmacokinetic/pharmacodynamic model of LY06006 in Chinese healthy subjects and postmenopausal osteoporotic women
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70275 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Yun Kuang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Bone Density Conservation Agents, Denosumab, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Scientific Research Program of Furong Laboratory, China, Hunan Provincial Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
LY06006, a biosimilar of denosumab, is a recombinant fully human monoclonal antibody targeting the receptor activator of nuclear factor κB ligand. LY06006 has completed Phase I and Phase III clinical studies. The objective of this study is to develop a pharmacokinetic (PK)/pharmacodynamic (PD) model of LY06006 in healthy male and osteoporotic female populations in China.
Methods
In total, 420 subjects were enrolled in this study, including 84 healthy male subjects from the Phase I study and 336 osteoporotic postmenopausal women from the Phase III study. A nonlinear mixed‐effects model was used for model development. The free serum concentration of LY06006 was used for PK analysis, and Type 1 collagen C‐terminal telopeptide was used for PD analysis.
Results
A two‐compartment Michaelis–Menten approximate model was used to describe the PK profiles of LY06006. Body weight was a significant covariate for the volume of distribution of the central compartment (V 1 ) and clearance. The estimated values of V 1 in postmenopausal women with osteoporosis were 0.87×, those observed in healthy male subjects. The indirect effect model was used to describe PK/PD relationship. Subjects' height significantly influenced the baseline values of C‐terminal telopeptide.
Conclusion
A population PK/PD model was developed in Chinese healthy male subjects and postmenopausal osteoporotic women. A 60‐mg dose of LY06006 achieves similar PD efficacy to denosumab. Clinical trial registration: Chinese Clinical Trial Registry ( https://www.chictr.org.cn/ ): ChiCTR2000039637, ChiCTR2000032882.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.
- Shandong Boan Biotechnology Co., Ltd, China.
- Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
- XiangYa School of Pharmaceutical Sciences, Central South University, Changsha, China.
ORCID-Profile: Qi Pei, Guo-Ping Yang
Förderung
- Scientific Research Program of Furong Laboratory, China
- Hunan Provincial Natural Science Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Kuang, Y., Liu, Y. X., Teng, Y. N., Zhang, L. F., Huang, J., Pei, Q., Guo, C. X., Peng, J. F., & Yang, G. P. (2026). Population pharmacokinetic/pharmacodynamic model of LY06006 in Chinese healthy subjects and postmenopausal osteoporotic women. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70275
Vancouver
Kuang Y, Liu YX, Teng YN, Zhang LF, Huang J, Pei Q, et al. Population pharmacokinetic/pharmacodynamic model of LY06006 in Chinese healthy subjects and postmenopausal osteoporotic women. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70275
BibTeX
@article{Kuang2026,
author = {Kuang, Yun and Liu, Ya-Xin and Teng, Yan-Ni and Zhang, Lin-Feng and Huang, Jie and Pei, Qi and Guo, Cheng-Xian and Peng, Jin-Fu and Yang, Guo-Ping},
title = {Population pharmacokinetic/pharmacodynamic model of LY06006 in Chinese healthy subjects and postmenopausal osteoporotic women},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70275}
}
EUVIMED